Navigation Links
AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
Date:9/25/2008

QUEBEC CITY, Sept. 25 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its President and CEO, Jrgen Engel, PhD, will present a company overview at BioContact Quebec on Thursday, October 2, 2008, at 2:00 pm (eastern time) in the Salle Frontenac of the Fairmont Le Chateau Frontenac hotel in Quebec City, Canada.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at http://www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
4. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
5. AEterna Zentaris Sells Quebec City Building for $7.1 million
6. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
7. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
8. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
9. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
10. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
11. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Boston Strategic Partners, Inc. (BSP), ... Economics and Outcomes Research (HEOR) and ‘big data’ to provide a variety of ... exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access to ...
(Date:8/18/2017)... FL (PRWEB) , ... August 18, 2017 , ... ... proudly announce that they will feature Federal Hybrids, Inc. in an upcoming episode, ... RFD-TV. , American Farmer will explore Federal Hybrids, the independent, family-owned seed ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... and personalized medicine, today announced the launch of a new breast cancer monitoring ... study’s goal is to evaluate the potential for early detection of recurrent breast ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... different cell type. Many treatments for specific cancers, such as breast, prostate, or ... treatment is androgen deprivation therapy for advanced prostate cancer. , This therapy ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
Breaking Biology News(10 mins):